These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 23581873)
1. Agomelatine reversal of escitalopram-induced apathy: a case report. De Berardis D; Valchera A; Fornaro M; Serroni N; Marini S; Moschetta FS; Martinotti G; Di Giannantonio M Psychiatry Clin Neurosci; 2013 Apr; 67(3):190-1. PubMed ID: 23581873 [No Abstract] [Full Text] [Related]
2. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Corruble E; de Bodinat C; Belaïdi C; Goodwin GM; Int J Neuropsychopharmacol; 2013 Nov; 16(10):2219-34. PubMed ID: 23823799 [TBL] [Abstract][Full Text] [Related]
3. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Quera-Salva MA; Hajak G; Philip P; Montplaisir J; Keufer-Le Gall S; Laredo J; Guilleminault C Int Clin Psychopharmacol; 2011 Sep; 26(5):252-62. PubMed ID: 21829106 [TBL] [Abstract][Full Text] [Related]
4. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671 [TBL] [Abstract][Full Text] [Related]
5. A case of hyponatremia associated with escitalopram. Nahshoni E; Weizman A; Shefet D; Pik N J Clin Psychiatry; 2004 Dec; 65(12):1722. PubMed ID: 15641882 [No Abstract] [Full Text] [Related]
6. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study. Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610 [TBL] [Abstract][Full Text] [Related]
8. Delirium during i. v. citalopram treatment: a case report. Delić M; Pregelj P Pharmacopsychiatry; 2013 Jan; 46(1):37-8. PubMed ID: 22821385 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Kennedy SH; Andersen HF; Lam RW J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428 [TBL] [Abstract][Full Text] [Related]
12. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164 [TBL] [Abstract][Full Text] [Related]
13. Re: Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression. Al-Adwani A Can J Psychiatry; 2005 Nov; 50(13):877; author reply 877-8. PubMed ID: 16483124 [No Abstract] [Full Text] [Related]
14. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials. Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920 [TBL] [Abstract][Full Text] [Related]
15. Repetitive transcranial magnetic stimulation as an antidepressant monotherapy in a patient with major depression, leucocytopenia and rhabdomyolysis. Mobascher A; Boecker J; Malevani J; Arends M; Klimke A; Cordes J Int J Neuropsychopharmacol; 2004 Dec; 7(4):527-9. PubMed ID: 15315718 [No Abstract] [Full Text] [Related]
16. Citalopram-induced major depression in a patient with panic disorder - a case report. Hofmann P; Conrad R Psychiatr Danub; 2012 Mar; 24(1):94-6. PubMed ID: 22447093 [No Abstract] [Full Text] [Related]
17. The safety of the electroconvulsive therapy-escitalopram combination. Masdrakis VG; Oulis P; Florakis A; Valamoutopoulos T; Markatou M; Papadimitriou GN J ECT; 2008 Dec; 24(4):289-91. PubMed ID: 18617866 [TBL] [Abstract][Full Text] [Related]
18. A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy. De Berardis D; Serroni N; Campanella D; Olivieri L; Moschetta FS; Conti CM; Conti P; Di Giannantonio M J Clin Psychopharmacol; 2012 Apr; 32(2):289-90. PubMed ID: 22388158 [No Abstract] [Full Text] [Related]
19. Photodistributed telangiectasia following use of escitalopram. Vaccaro M; Calapai G; Guarneri F; Mannucci C; Lentini M; Cannavò SP Allergol Int; 2016 Jul; 65(3):336-7. PubMed ID: 26888670 [No Abstract] [Full Text] [Related]
20. Escitalopram: a review of its use in the management of major depressive disorder in adults. Garnock-Jones KP; McCormack PL CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]